, Tracking Stock Market Picks
Enter Symbol:
PROLOR Biotech, Inc. (PBTH) [hlAlert]

up 63.94 %

PROLOR Biotech, Inc. (PBTH) rated Buy with price target $16 by Morgan Joseph

Posted on: Tuesday,  Jul 12, 2011  12:25 PM ET by Morgan Joseph

Morgan Joseph rated Buy PROLOR Biotech, Inc. (AMEX: PBTH) on 07/12/2011, when the stock price was $5.02. Since
then, PROLOR Biotech, Inc. has gained 63.94% as of 08/29/2013's recent price of $8.23.
If you would have followed this Morgan Joseph's recommendation on PBTH, you would have gained 63.94% of your investment in 779 days.

Prolor Biotech, Inc. (Prolor), formerly Modigene Inc. is a development-stage biopharmaceutical company, utilizing technology to develop versions of therapeutic proteins. The Company uses Carboxyl Terminal Peptide (CTP) technology to develop new versions of therapeutic proteins. As of December 31, 2009, the Company was focused on the development of products, including Human Growth Hormone (hGH), Interferon β, Factor VIIa, Factor IX, Erythropoietin (EPO), Anti-Obesity Peptide and Glucagon-Like Peptide-1 (GLP-1).

Morgan Joseph is committed to providing timely, objective and actionable investment advice on the companies and securities we follow. Our team of equity analysts covers a growing universe of stock issues across a broad range of industry sectors. As a middle market-focused firm, our approach is not to publish research on as many companies as possible within a number of industry sectors. Rather, our research analysts distinguish themselves by zeroing in on quality companies with growth prospects or which present special situations. These companies often lack a research following. This enables our analysts to provide insight to investors in companies that are not well understood nor fairly valued.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/12/2011 12:25 PM Buy
5.02 16.00
as of 12/30/2011
1 Week up  6.75 %
1 Month down  -2.06 %
3 Months up  4.91 %
1 YTD down  -14.94 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy